Results 11 to 20 of about 4,377,369 (241)

AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome [PDF]

Hematology, 2022
Objectives Acute myeloid leukemia (AML) with inv(16)/t(16;16) is among the most frequent AML subtypes. It is recognized by the detection of the CBFB-MYH11 fusion which confers a favorable prognosis, irrespective of the presence of secondary cytogenetic ...
Nada Assaf, Christine Lefebvre, Victoria Raggueneau, Geoffroy Guignedoux, Alice Marceau-Renaut, Simon Chevalier, Sylvie Tondeur, Dominique Bories, Riad Benramdane, Philippe Rousselot, Christine Terré   +10 more
doaj   +2 more sources

Addiction of t(8;21) and inv(16) Acute Myeloid Leukemia to Native RUNX1 [PDF]

Cell Reports, 2013
The t(8;21) and inv(16) chromosomal aberrations generate the oncoproteins AML1-ETO (A-E) and CBFβ-SMMHC (C-S). The role of these oncoproteins in acute myeloid leukemia (AML) etiology has been well studied.
Oren Ben-Ami, Dan Friedman, Dena Leshkowitz, Dalia Goldenberg, Kira Orlovsky, Niv Pencovich, Joseph Lotem, Amos Tanay, Yoram Groner   +8 more
doaj   +2 more sources

Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature [PDF]

Clinical Medicine Insights: Blood Disorders, 2017
Systemic mastocytosis (SM) is a condition associated with clonal neoplastic proliferation of mast cells. In up to 40% of systemic mastocytosis cases, an associated clonal hematological disease of non–mast cell lineage, such as acute myeloid leukemia (AML)
Feryal Abbas Ibrahim Hilmi, Ahmad Al-Sabbagh, Dina Sameh Soliman, Hesham Al Sabah, Omar Mohammad Ismail, Mohamed Yassin, Halima El-Omri   +6 more
doaj   +2 more sources

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). [PDF]

Blood Adv, 2021
Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40%
Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS.   +46 more
europepmc   +4 more sources

Abnormal eosinophils with immature eosinophilic granules in chronic myeloid leukemia in accelerated phase

Clinical Case Reports, 2021
Abnormal eosinophils with immature eosinophilic granules are typically observed in acute myeloid leukemia with inv (16) (p13.1q22) or t (16;16) (p13.1;q22) but can also be seen in chronic myeloid leukemia without inv (16) or t (16;16).
Jennifer Cai, Ping Ji, Sarah Tomassetti, Xin Qing   +3 more
doaj   +1 more source

inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice.

Blood, 2016
Favorable-risk human acute myeloid leukemia (AML) engrafts poorly in currently used immunodeficient mice, possibly because of insufficient environmental support of these leukemic entities.
Ellegast JM, Rauch PJ, Kovtonyuk LV, Müller R, Wagner U, Saito Y, Wildner-Verhey van Wijk N, Fritz C, Rafiei A, Lysenko V, Dudkiewicz E, Theocharides AP, Soldini D, Goede JS, Flavell RA, Manz MG.   +15 more
europepmc   +2 more sources

HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. [PDF]

Cell Stem Cell, 2015
SummaryAcute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy.
Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, Liu H, Ho Y, McDonald T, Lin A, Marcucci G, Bhatia R, Huang WJ, Chang CI, Kuo YH.   +14 more
europepmc   +2 more sources

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions

Turkish Journal of Hematology, 2022
Objective: This study was undertaken with the aim of better understanding the genomic landscape of core-binding factor (CBF) acute myeloid leukemia (AML).
Wei Qin, Xiayu Chen, Hong Jie Shen, Zheng Wang, Xiaohui Cai, Naike Jiang, Haiying Hua   +6 more
doaj   +1 more source

Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world

Cancer Medicine, 2023
Background Chromosomal translocations involving core binding factor (CBF) genes account for 15% of adult acute myeloid leukemia (AML) cases in China. Despite being classified as favorable‐risk by European Leukemia Net (ELN), CBF‐AML patients have a 40 ...
Yamei Zhai, Qingya Wang, Li Ji, Hanyun Ren, Yujun Dong, Fan Yang, Yue Yin, Zeyin Liang, Qian Wang, Wei Liu, Yan Mei, Lu Zhang, Yuan Li   +12 more
doaj   +1 more source

inv(16)(p13q24) CBFA2T3/GLIS2 [PDF]

, 2013
Review on inv(16)(p13q24) CBFA2T3/GLIS2, with data on clinics, and the genes ...
Huret, JL
core   +1 more source